GnRH agonists initially stimulate the release of LH and FSH, leading to a temporary increase in sex steroids. However, with continuous administration, they cause desensitization of the GnRH receptors, resulting in decreased production of LH and FSH and subsequent reduction in sex steroid levels. This mechanism helps in halting premature sexual development in children with CPP.
